Currently, out of the existing stock ratings of Jason Kolbert - 110 which are a Buy (89.43%), 12 which are a Hold (9.76%), 1 which are a Sell (0.81%)

Jason Kolbert

Work Performance Price Targets & Ratings Chart

Analyst Jason Kolbert works at DAWSON JAMES and is covering the Healthcare sector with 239 price targets and ratings displayed on 30 stocks. Previously, Jason Kolbert worked at MAXIM GROUP.

Jason Kolbert's average stock forecast success ratio is 64.47% with an average time for price targets to be met of 337.5 days.

Most recent stock forecast was given on ISR, IsoRay at 02-Mar-2022.

Wall Street Analyst Jason Kolbert

Analyst best performing recommendations are on MNKD (MANNKIND).
The best stock recommendation documented was for MNKD (MANNKIND) at 10/3/2017. The price target of $4 was fulfilled within 2 days with a profit of $1.18 (41.84%) receiving and performance score of 209.22.

Average potential price target upside

of $512.5 (58.85%) on PSTV (PLUS THERAPEUTICS).
of $47.25 (38.63%) on AEZS (AETERNA ZENTARIS).
of $25.13 (109.63%) on SNGX.

ADMP Adamis Pharmaceuticals AEZS Aeterna Zentaris ATHX Athersys BCLI Brainstorm Cell Therapeutics BLRX BioLineRx Ltd CTXR Citius Pharmaceuticals FBIO Fortress Biotech GILD Gilead Sciences GLMD Galmed Pharmaceuticals Ltd INO Inovio Pharmaceuticals ISR IsoRay MESO Mesoblast MNKD MannKind NTEC OMER Omeros PSTI Pluristem Therapeutics SRNE Sorrento Therapeutics ACHN CLBS Caladrius Biosciences TEVA Teva Pharmaceutical Industries VRTX Vertex Pharmaceuticals AVXL Anavex Life Sciences PSTV Plus Therapeutics PRPH BCDA ADMA ADMA Biologics BGNE BeiGene, Ltd CFRX CHEK CheckCap Ltd SNGX

Show more stocks

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average time for PT to be met

Performance score

Jason Mccarthy (MAXIM GROUP)